Concerto HealthAI and Pfizer have entered a precision oncology collaboration.
Pfizer will benefit from the deal through gaining Concerto HealthAI’s eurekaHealth AI platform and Real-World Data, which can be used to help identify new and more precise treatment options as well as accelerate completion times for various outcomes studies.
The deal marks Concerto’s second AI collaboration with a big pharma company in the last week, as the company in late March announced an agreement with Bristol-Myers Squibb to use real-world evidence to accelerate clinical trials and improve precision treatment for a range of cancers.
The collaboration will develop new synthetic control arm and prospective study designs, for both pre- and post-approval research, based on real-world data outcomes for therapeutics. Concerto announced that the plan is to build on work in study designs based on real-world data that CancerLinQ, Concerto HealthAI and others have undertaken in collaboration with U.S. Food and Drug Administration (FDA).
“Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.
“We are pleased to work with Concerto HealthAI –– to accelerate insights and outcomes studies that may lead to a more comprehensive understanding of patients’ experience with our medicines.”
A Concerto HealthAI-Pfizer joint steering committee will oversee the collaboration, with the first outcomes for research and publications expected in early 2020.
